72C Stock Overview
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Eiger BioPharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.18 |
| 52 Week High | US$34.20 |
| 52 Week Low | US$4.05 |
| Beta | 1.84 |
| 1 Month Change | 0% |
| 3 Month Change | -1.90% |
| 1 Year Change | -74.88% |
| 3 Year Change | -97.23% |
| 5 Year Change | -98.43% |
| Change since IPO | -98.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 72C | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.8% |
| 1Y | -74.9% | -15.8% | 1.0% |
Return vs Industry: 72C underperformed the German Biotechs industry which returned 34.8% over the past year.
Return vs Market: 72C underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| 72C volatility | |
|---|---|
| 72C Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 72C has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 72C's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 51 | David Apelian | www.eigerbio.com |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia.
Eiger BioPharmaceuticals, Inc. Fundamentals Summary
| 72C fundamental statistics | |
|---|---|
| Market cap | €1.79m |
| Earnings (TTM) | -€80.47m |
| Revenue (TTM) | €13.62m |
0.1x
P/S Ratio0.0x
P/E RatioIs 72C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 72C income statement (TTM) | |
|---|---|
| Revenue | US$14.67m |
| Cost of Revenue | US$268.00k |
| Gross Profit | US$14.40m |
| Other Expenses | US$101.05m |
| Earnings | -US$86.65m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -58.57 |
| Gross Margin | 98.17% |
| Net Profit Margin | -590.80% |
| Debt/Equity Ratio | -2,539.5% |
How did 72C perform over the long term?
See historical performance and comparison